Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Receptor radionuclide therapy with 177Lu-DOTATATE in sst2-positive tumors
2007-005517-20Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in Neoplasm, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: ORR. Started Jan 2008; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neoplasm
Beyond the preview
Go deeper on 2007-005517-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005517-20.